For the quarter ending 2026-03-31, XERS had $708K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 2,234 | 11,081 | 621 | -11,148 |
| Depreciation | 337 | 335 | 338 | 640 |
| Deferred income tax expense (benefit) | - | 0 | 0 | 0 |
| Amortization of intangible assets | 2,710 | 2,711 | 2,711 | 5,421 |
| Amortization of premium/discount on investments | - | 0 | 0 | 0 |
| Loss on debt extinguishment, net | - | 0 | - | - |
| Amortization of debt discount and debt issuance costs | 889 | 866 | 843 | 1,664 |
| Change in fair value of contingent value rights | - | 0 | 0 | 0 |
| Amortization of operating right-of-use assets | 163 | 151 | 140 | 246 |
| Other | - | 0 | - | - |
| Stock-based compensation | 4,140 | 5,272 | 7,643 | 9,451 |
| Trade accounts receivable | 5,245 | -2,701 | 703 | 12,633 |
| Prepaid expenses and other current assets | -145 | -1,253 | 5,153 | -1,803 |
| Inventory | -851 | 4,011 | 4,085 | 11,190 |
| Accounts payable | 4,250 | -1,698 | 1,996 | -367 |
| Accrued returns reserve | - | - | -566 | 700 |
| Other accrued liabilities | -1,497 | 3,704 | 2,832 | -3,230 |
| Accrued trade discounts and rebates | 6,256 | -3,988 | 11,930 | 8,445 |
| Accrued returns reserve | -246 | -113 | - | - |
| Increase (decrease) in supply agreement liabilities | - | 0 | - | - |
| Operating lease liabilities | -434 | -422 | -412 | -742 |
| Other | -4,683 | 2,335 | 297 | 1,091 |
| Net cash provided by (used in) operating activities | 9,870 | 20,043 | 18,432 | -9,849 |
| Capital expenditures | -325 | -333 | -71 | -292 |
| Purchases of investments | - | 0 | 0 | 0 |
| Sales and maturities of investments | - | 0 | 0 | 0 |
| Net cash used in investing activities | -325 | -333 | -71 | -292 |
| Proceeds from debt refinancing | - | 0 | 0 | 0 |
| Payment of debt discount | - | 0 | 0 | 0 |
| Payments of debt issuance costs | - | 0 | - | - |
| Proceeds from issuance of employee stock purchase plan shares | - | 690 | 0 | 830 |
| Proceeds from exercise of stock options | 847 | 584 | 5,161 | 5,833 |
| Proceeds from issuance of warrants | 7,333 | 0 | 9,167 | - |
| Repurchase of common stock withheld for taxes | 17,017 | 1,540 | 478 | 8,858 |
| Net cash used in financing activities | -8,837 | -266 | 13,850 | -2,195 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 708 | 19,444 | 32,211 | -12,336 |
| Cash, cash equivalents and restricted cash, beginning of year | 115,063 | 95,619 | 75,744 | - |
| Cash, cash equivalents and restricted cash, end of quarter | 115,771 | 115,063 | 95,619 | - |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)